Skip to main content
. 2019 Dec 18;267(4):1070–1079. doi: 10.1007/s00415-019-09671-9

Table 2.

Percentage of patients with Norfolk QOL-DN item responses indicating substantial impairment at week 66, and change in percentage from baseline to week 66, by treatment arm

Item # Content Week 66 Change from baseline to week 66
Inotersen (%) Placebo (%) Inotersen (%) Placebo (%)
8 Pain kept you awake at night 15.5 36.5 − 1.7 7.2
9 Touch of bed sheets bothered you 11.9 26.9 − 1.6 8.0
10 Injured yourself without feeling 14.3 19.2 1.0 5.4
11 Symptoms affect usual activity 35.7 50.0 6.9 20.7
12 Difficult movement with fingers 46.4 63.5 1.7 18.6
13 Felt unsteady on your feet 48.8 67.3 − 0.7 17.3
14 Problem getting out of a chair 50.0 61.5 3.3 11.5
15 Problem walking down stairs 41.7 57.7 0.7 16.3
16 Unable to feel your feet 45.2 40.4 10.3 0.7
17 Unable to tell hot (hands) 15.5 25.0 1.1 4.3
18 Unable to tell hot (feet) 40.5 38.5 − 0.5 0.5
19 Problem with vomiting 6.0 5.8 2.1 2.3
20 Problem with diarrhea 20.2 30.8 − 1.7 15.3
21 Problem with fainting/dizziness 10.7 19.2 − 8.3 10.6
22 Difficulty bathing 22.6 34.6 − 0.2 17.4
23 Difficulty dressing 21.4 34.6 1.4 22.5
24 Difficulty walking 40.5 59.6 3.9 28.6
25 Difficulty getting on/off toilet 22.6 36.5 2.6 15.8
26 Difficulty using utensils 19.0 30.8 − 1.0 10.1

For the selected Norfolk QOL-DN items, substantial impairment was defined as a response of ‘moderate problem’ or ‘severe problem’